A recent study by researchers at Brigham and Women’s Hospital and Harvard Medical School, both based in Boston, found only 43% of cancer drugs granted accelerated FDA approval demonstrated clinical benefit in confirmatory trials.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
